A-412,997 is a drug which acts as a dopamine agonist that is used in scientific research. It is the first drug developed that is a highly selective agonist for the D4 subtype, with significantly improved selectivity over older D4-preferring compounds such as PD-168,077 and CP-226,269.[1] In animal tests it improved cognitive performance in rats to a similar extent as methylphenidate, but without producing place preference or other signs of abuse liability.[2][3] Also unlike other dopamine agonists, selective D4 agonists do not cause side effects such as sedation and nausea, and so might have advantages over older dopamine agonist drugs.[4]
References
↑Moreland RB, Patel M, Hsieh GC, Wetter JM, Marsh K, Brioni JD (September 2005). "A-412997 is a selective dopamine D4 receptor agonist in rats". Pharmacology Biochemistry and Behavior. 82 (1): 140–7. doi:10.1016/j.pbb.2005.08.001. PMID16153699. S2CID10270715.
↑Browman KE, Curzon P, Pan JB, Molesky AL, Komater VA, Decker MW, etal. (September 2005). "A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats". Pharmacology Biochemistry and Behavior. 82 (1): 148–55. doi:10.1016/j.pbb.2005.08.002. PMID16154186. S2CID31796938.
↑Woolley ML, Waters KA, Reavill C, Bull S, Lacroix LP, Martyn AJ, etal. (December 2008). "Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat". Behavioural Pharmacology. 19 (8): 765–76. doi:10.1097/FBP.0b013e32831c3b06. PMID19020411. S2CID36272297.
